Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB Announces Third Research Collaboration with Harvard University

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.

UCB has announced that it has launched a third collaborative research project with Harvard that builds upon the innovative Research Alliance they both signed in 2011.

The third research project named ‘Mining the Human Microbiome” will be headed by Christophe Benoist, M.D., Ph.D., Dennis Kasper, M.D., and Diane Mathis, Ph.D., all Professors in the Division of Immunology in the Department of Microbiology and Immunobiology at Harvard Medical School.

The team will be studying the human microbiome in the intestine, classifying new species in studying their impact on the immune system in order to identify new drugs for preventing or treating immunological diseases.

UCB will provide up to $4.5 million over three years to fund the project.

A microbiome is the totality of microbes, their genetic elements and environmental interactions in a particular environment. Adult humans contain, on average, some 100 trillion bacteria in their intestines alone.

These bacteria are believed to be central to their host’s well-being while heavily influencing the immune system.

The Harvard investigators plan to systematically mine the human microbiome to look for new immunomodulatory molecules in the intestine with potential therapeutic applications.

In order to do so, their labs have designed an interdisciplinary project using recent technological advances in next generation sequencing, whole-genome and single molecule transcript profiling and polychromatic flow cytometry.

“We hope this project will fundamentally shift the paradigm of drug development for immunological diseases, exploiting naturally occurring molecules evolutionarily designed to thwart or harness the immune system,” said the Harvard investigators.

“If found, these molecules would be of enormous potential for probing immune system function, therapeutic application and as a preventative therapy.”

“We are pleased to enter into this, our third innovative collaboration with UCB, which once again couples leaders in academia and industry to drive translation and advance frontier research from the lab to the clinic,” said Isaac T. Kohlberg, Harvard’s Chief Technology Development Officer and head of its Office of Technology Development.

Kohlberg continued, "Harvard's collaboration with UCB is a model of how universities can work with industry to advance the progress of medicine and serve the public interest, which is fundamental to Harvard’s core mission".

“This is the third collaboration we have initiated with Harvard in the last 18 months. Our continued alliance with this renowned institution is testimony to our belief in Harvard’s excellence in scientific research and in the strength of our open innovation model,” said Ismail Kola, President of UCB NewMedicines, UCB’s research and early development division.

Kola continued, “Microbiome is one of modern science’s most exciting fields of research and we are confident that this new collaboration will benefit patients by enabling us to meet unmet health care needs in immunology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!